RESCUE: A Randomized, Blinded, Placebo-controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy

A Phase II, randomized, blinded, placebo-controlled, parallel group study with patients experiencing a large vessel occlusion acute ischemic stroke who are selected for endovascular revascularization. Participants will be given a 48 h infusion of either 0.5 mL/kg/h RNS60 (up to a maximum of 60 mL/h), 1 mL/kg/h RNS60 (up to a maximum of 120 mL/h), or 1 mL/kg/h (up to a maximum of 120 mL/h) placebo (normal saline) starting within 30 minutes of consent after confirmation of candidacy for endovascular thrombectomy.

Start Date07 Jul 2021

Sponsor / Collaborator

Revalesio Corp.

NCT03456882

/ CompletedPhase 2IIT

The Effect of RNS60 on ALS Biomarkers

Amyotrophic Lateral Sclerosis (ALS) is a rare lethal neurodegenerative disease involving inflammation. Riluzole, the only drug for ALS, improves median survival by 3 months. This prompts new treatments of ALS. RNS60 is an experimental drug with favorable effects in preclinical studies of neuroinflammation and neurodegeneration. Based on significant efficacy demonstrated in preclinical studies and its excellent clinical safety profile, RNS60 is a promising candidate for a drug to treat ALS. Developing a pharmacodynamic marker will be a first and important step for dose finding and exploration of the mechanism of action in human, and pave the way to trials measuring drug efficacy.
The Investigator propose a multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase II trial. The study centers will be located in Italy and at Massachusetts General Hospital (MGH) in Boston. A total of 142 ALS patients will be randomly assigned to RNS60 or placebo (administered by intravenous infusion once/week and inhaled via nebulization every morning for 24 weeks). All participants will also take riluzole (50-mg tablet twice/day). Blood samples for biomarker analysis (protein, RNA) will be collected in the screening period, on day 1, week 4,12 and 24. Both safety and potential therapeutic effects of RNS60 will be also assessed.

Start Date30 May 2017

Sponsor / Collaborator

The Amyotrophic Lateral Sclerosis Association

100 Clinical Results associated with RNS-60

100 Translational Medicine associated with RNS-60

100 Patents (Medical) associated with RNS-60

838

Literatures (Medical) associated with RNS-60

01 Nov 2024·Brain, Behavior, and Immunity

Long-term survival of participants in a phase II randomized trial of RNS60 in amyotrophic lateral sclerosis

Article

BACKGROUNDPositive effects of RNS60 on respiratory and bulbar function were observed in a phase 2 randomized, placebo-controlled trial in people with amyotrophic lateral sclerosis (ALS).OBJECTIVEto investigate the long-term survival of trial participants and its association with respiratory status and biomarkers of neurodegeneration and inflammation.STUDY DESIGN AND SETTINGSA randomized, double blind, phase 2 clinical trial was conducted. Trial participants were enrolled at 22 Italian Expert ALS Centres from May 2017 to January 2020. Vital status of all participants was ascertained thirty-three months after the trial's last patient last visit (LPLV). Participants were patients with Amyotrophic Lateral Sclerosis, classified as slow or fast progressors based on forced vital capacity (FVC) slope during trial treatment. Demographic, clinical, and biomarker levels and their association with survival were also evaluated.RESULTSMean duration of follow-up was 2.8 years. Long-term median survival was six months longer in the RNS60 group (p = 0.0519). Baseline FVC, and rates of FVC decline during the first 4 weeks of trial participation, were balanced between the active and placebo treatment arms. After 6 months of randomized, placebo-controlled treatment, FVC decline was significantly slower in the RNS60 group compared to the placebo group. Rates of FVC progression during the treatment were strongly associated with long-term survival (median survival: 3.7 years in slow FVC progressors; 1.6 years in fast FVC progressors). The effect of RNS60 in prolonging long-term survival was higher in participants with low neurofilament light chain (NfL) (median survival: >4 years in low NfL - RNS60 group; 3.3 years in low NfL - placebo group; 1.9 years in high NfL - RNS60 group; 1.8 years in high NfL - placebo group) and Monocyte Chemoattractant Protein-1 (MCP-1) (median survival: 3.7 years in low MCP-1 - RNS60 group; 2.3 years in low MCP-1 - placebo group; 2.8 years in high MCP-1 - RNS60 group; 2.6 years in high MCP-1 - placebo group) levels at baseline.CONCLUSIONS AND RELEVANCEIn this post-hoc analysis, long term survival was longer in participants randomized to RNS60 compared with those randomized to placebo and was correlated with slower FVC progression rates, suggesting that longer survival may be mediated by the drug's effect on respiratory function. In these post-hoc analyses, the beneficial effect of RNS60 on survival was most pronounced in participants with low NfL and MCP-1 levels at study entry, suggesting that this could be a subgroup to target in future studies investigating the effects of RNS60 on survival.TRIAL REGISTRATIONStudy preregistered on 13/Jan/2017 in EUDRA-CT (2016-002382-62). The study was also registered at ClinicalTrials.gov number NCT03456882.

01 Jul 2024·Archives of Disease in Childhood - Fetal and Neonatal Edition

Assessing the influence of abdominal compression on time to return of circulation during resuscitation of asphyxiated newborn lambs: a randomised preclinical study

Article

Author: Roberts, Calum T ; Kluckow, Martin ; Polglase, Graeme R ; Badurdeen, Shiraz ; Camm, Emily ; Hwang, Colin ; Gill, Andrew W ; Galinsky, Robert ; Crossley, Kelly J ; Hooper, Stuart B ; Brian, Yoveena ; Blank, Douglas A

ObjectiveDuring neonatal resuscitation, the return of spontaneous circulation (ROSC) can be achieved using epinephrine which optimises coronary perfusion by increasing diastolic pressure. Abdominal compression (AC) applied during resuscitation could potentially increase diastolic pressure and therefore help achieve ROSC. We assessed the use of AC during resuscitation of asystolic newborn lambs, with and without epinephrine.MethodsNear-term fetal lambs were instrumented for physiological monitoring and after delivery, asphyxiated until asystole. Resuscitation was commenced with ventilation followed by chest compressions. Lambs were randomly allocated to: intravenous epinephrine (20 µg/kg, n=9), intravenous epinephrine+continuous AC (n=8), intravenous saline placebo (5 mL/kg, n=6) and intravenous saline+AC (n=9). After three allocated treatment doses, rescue intravenous epinephrine was administered if ROSC had not occurred. Time to achieve ROSC was the primary outcome. Lambs achieving ROSC were ventilated and monitored for 60 min before euthanasia. Brain histology was assessed for micro-haemorrhage.ResultsUse of AC did not influence mean time to achieve ROSC (epinephrine lambs 177 s vs epinephrine+AC lambs 179 s, saline lambs 602 s vs saline+AC lambs 585 s) or rate of ROSC (nine of nine lambs, eight of eight lambs, one of six lambs and two of eight lambs, respectively). Application of AC was associated with higher diastolic blood pressure (mean value >10 mm Hg), mean and systolic blood pressure and carotid blood flow during resuscitation. Cortex and deep grey matter micro-haemorrhage was more frequent in AC lambs.ConclusionUse of AC during resuscitation increased diastolic blood pressure, but did not impact time to ROSC.

01 Mar 2024·The Spine Journal

Spinal decompression surgery may alleviate vasopressor-induced spinal hemorrhage and extravasation during acute cervical spinal cord injury in rats

Article

Author: Lee, Po-Hsuan ; Lee, Kun-Ze ; Ko, Chia-Chen ; Lee, Jung-Shun

BACKGROUNDCervical spinal injury often disrupts the supraspinal vasomotor pathways projecting to the thoracic sympathetic preganglionic neurons, leading to cardiovascular dysfunction. The current guideline is to maintain the mean arterial blood pressure at 85 to 90 mmHg using a vasopressor during the first week of the injury. Some studies have demonstrated that this treatment might be beneficial to alleviate secondary injury and improve neurological outcomes; however, elevation of blood pressure may exacerbate spinal hemorrhage, extravasation, and edema, exacerbating the initial injury.PURPOSEThe present study was designed to (1) examine whether vasopressor administration exacerbates spinal hemorrhage and extravasation; (2) evaluate whether spinal decompression surgery relieves vasopressor-induced spinal hemorrhage and extravasation.STUDY DESIGNIn vivo animal study.METHODSAnimals received a saline solution or a vasopressor (phenylephrine hydrochloride, 500 or 1000 μg/kg, 7 mL/kg/h) after mid-cervical contusion with or without spinal decompression (ie, incision of the dura and arachnoid mater). Spinal cord hemorrhage and extravasation were examined by expression of Evans blue within the spinal cord section.RESULTSThe results demonstrated that cervical spinal contusion significantly reduced the mean arterial blood pressure and induced spinal hemorrhage and extravasation. Phenylephrine infusion significantly elevated the mean arterial blood pressure to the preinjury level within 15 to 60 minutes postcontusion; however, spinal hemorrhage and extravasation were more extensive in animals that received phenylephrine than in those that received saline. Notably, spinal decompression mitigated spinal hemorrhage and extravasation in contused rats who received phenylephrine.CONCLUSIONSThese data indicate that, although phenylephrine can prevent hypotension after cervical spinal injury, it also causes excess spinal hemorrhage and extravasation.CLINICAL SIGNIFICANCESpinal decompressive surgery seemed to minimize the side effect of phenylephrine as vasopressor treatment during acute spinal cord injury.

News (Medical) associated with RNS-60

05 Feb 2025

·www.prnewswire.com

Revalesio Announces New Analyses from Phase 2 RESCUE Study of RNS60 in Patients with Acute Ischemic Stroke in Oral Presentation at the International Stroke Conference 2025

Lowering of infarct growth – brain tissue loss – by 50% in patients treated in less than 12 hours following last known well Lowering of infarct growth correlated with clinically meaningful improvements in several functional stroke measures that evaluate a patient's recovery TACOMA, Wash., Feb. 5, 2025 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced new analyses of its completed Phase 2 RESCUE clinical trial of RNS60 in acute ischemic stroke (AIS) patients, demonstrating a nominally significant lowering of infarct growth, or brain tissue loss, in patients treated in less than 12 hours following the last time a patient was known to be well. The lowering of infarct growth correlated with clinically meaningful improvements in several functional stroke measures that evaluate a patient's recovery, including the modified Rankin Scale (mRS), Barthel Index (BI), and National Institute of Health Stroke Scale (NIHSS). These results were presented today during an oral presentation at the International Stroke Conference (ISC) 2025 in Los Angeles, CA. "This analysis of the RESCUE trial adds further information regarding the beneficial effects of RNS60, confirming that it has favorable effects on MRI-confirmed ischemic lesion growth that translated into improved clinical outcomes," said Dr. Marc Fisher, Neurologist Beth Israel Deaconess Medical Center, Harvard Medical School, and former World Stroke Organization President. "These are exciting results that suggest that RNS60 should be evaluated in a large Phase 3 clinical trial that will hopefully confirm its benefits and lead to approval as the first therapeutic agent in decades to demonstrate significant efficacy in improving outcomes for acute ischemic stroke patients." In RESCUE, a multi-center, double-blinded, placebo-controlled, randomized Phase 2 clinical trial, Revalesio evaluated the safety and initial efficacy of RNS60. Eighty-two participants with AIS eligible for endovascular thrombectomy (EVT) were enrolled and received intravenous RNS60 0.5 mL/kg/h (low dose), RNS60 1.0 mL/kg/h (high dose), or placebo starting before completion of the EVT and continuing for 48 hours. The trial had two primary endpoints: safety and mortality. Secondary endpoints for the study evaluated disability based on the well-established modified Rankin Scale (mRS), change in the size of the stroke as measured by MRI at 48 hours, and additional standard stroke scales (BI and NIHSS). Highlights from the oral presentation include: RNS60 high dose significantly lowered infarct growth by 50% (nominal p<0.05) when compared to placebo based on imaging performed at approximately 48 hours compared to immediately post EVT both in patients treated within 12 hours and 24 hours of last known well. RNS60 high dose was also numerically better than placebo for each prespecified functional endpoint: Modified Rankin Score at Day 90: 72% of subjects on RNS60 high dose were independent (mRS of 0-2) at Day 90 compared to 37% on placebo. Barthel Index at Day 90: 72% of subjects on RNS60 high dose returned to normal activities of daily living (BI³ 95) compared to 37% on placebo. Patient Health Status at Day 90 (as measured by the EQ-5D-5L Index with 1.0 being ideal) was 0.79 for RNS60 subjects and 0.57 for placebo. RNS60 was safe and well tolerated Details of the oral presentation at ISC 2025 are below: "As the number one cause of disability worldwide, the impact of stroke is staggering, accounting for $721 billion annually to the global healthcare system. Additionally, more than 80% of patients in the U.S. have no treatment options following a stroke, underscoring the significant need for new and effective treatment options," said Bert van den Bergh, Revalesio's Executive Chairman of the Board of Directors, and former President of Neuroscience Products at Eli Lilly and Company. "These highly encouraging results further demonstrate the potential of RNS60 to greatly reduce the likelihood of disability in patients following a stroke, and we plan to advance RNS60 into a Phase 3 clinical trial in order to bring this promising therapy to patients." Initial topline results of the RESCUE Phase 2 study were presented as a late-breaking oral presentation at ISC 2024, which evaluated patients who were 24 hours from last known well. About RNS60 RNS60 is an investigational therapeutic being developed to provide disease modifying and potentially restorative treatments for neurological diseases. In preclinical studies, RNS60 activated intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protected neurons and oligodendrocytes and modulated the activity of immune cells to restore homeostasis. About Revalesio Revalesio is a clinical-stage pharmaceutical company with a vision to change the future of treatment for acute and chronic neurological disorders. The company's lead clinical program for RNS60 is ischemic stroke with additional programs in ALS and other neurological disorders. The company's pioneering technology, founded in physics, addresses fundamental mechanisms involved with proper cellular function to slow disease progression and improve quality of life. For more information, please visit revalesio.com and engage with us on LinkedIn. Media: Lori Murray [email protected] SOURCE Revalesio Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 2

09 Oct 2024

·www.prnewswire.com

Revalesio's Investigational Treatment RNS60 Protects Mitochondria in Preclinical Model of Amyotrophic Lateral Sclerosis (ALS)

Results Presented in an Oral Presentation at the Society for Neuroscience Annual Meeting RNS60 Protected Motor Neurons and Neuromuscular Junctions and Reduced Neuroinflammation TACOMA, Wash., Oct. 9, 2024 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced new data showing that Revalesio's investigational therapeutic, RNS60, protected motor neurons in the prpTDP-43A315T-UeGFP mouse model of ALS. PrpTDP-43A315T-UeGFP mice express a mutation of the human TDP43 gene and develop progressive motor neuron degeneration, leading to gait abnormalities, muscle weakness, and eventually death, mimicking key features of ALS. TDP43-associated pathology is found in approximately 97% of people with ALS. The results were presented today during the Nanosymposium ALS Therapeutics at the Society for Neuroscience Annual Meeting. "There is a great need for treatment options to slow the progression of ALS," said Hande Ozdinler, Ph.D., Associate Professor of Neurology at Northwestern University Feinberg School of Medicine and Principal Investigator of the study. "These promising preclinical findings warrant further investigation of the potential role of RNS60 in protecting motor neurons and preserving mitochondrial function, key factors in the pathogenesis of ALS." "These exciting results suggest that RNS60 has potential to mitigate neurodegeneration due to TDP-43 pathology," said Mukesh Gautam, PhD, Research Assistant Professor of Neurology at Northwestern University Feinberg School of Medicine and presenting author at the Society for Neuroscience Annual Meeting. "Since TDP-43 pathology contributes to a large population of both familial and sporadic ALS patients, these results are particularly promising." In this study, 30-day old prpTDP-43A315T-UeGFP mice showing signs of degeneration were treated with RNS60 every other day for 60 days. Immunohistochemistry was performed to quantitatively assess activated microglia (immune cells that patrol the central nervous system [CNS] for pathogens and damage) and activated astrocytes (cells in the CNS that perform metabolic, structural, homeostatic, and neuroprotective tasks). Ultrastructural integrity of neuronal mitochondria was studied via electron microscopy. RNS60 treatment significantly a) improved mitochondrial ultrastructure in the motor neurons, b) reduced the extent of astrogliosis and microgliosis in mice and c) protected health and stability of upper motor neurons and neuromuscular junctions compared to placebo-treated mice. "These results add to the growing body of preclinical and clinical evidence that RNS60 may provide neuroprotective effects in ALS," said Bert van den Bergh, Revalesio's Executive Chairman on the Board of Directors, and former President of Neuroscience Products at Eli Lilly and Company. "We are simultaneously advancing RNS60 in planned clinical trials for the treatment of patients with ALS and ischemic stroke with the goal of improving the lives of people with these devastating conditions." About RNS60 RNS60 is an investigational therapeutic being developed to provide disease modifying and potentially restorative treatments for neurological diseases. In preclinical studies, RNS60 activated intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protected neurons and oligodendrocytes and modulated the activity of immune cells to restore homeostasis. RNS60 has been granted Orphan Drug and Fast Track designations for ALS from the U.S. Food and Drug Administration. About Revalesio Revalesio is a clinical-stage pharmaceutical company with a vision to change the future of treatment for acute and chronic neurological disorders. The company's lead clinical program for RNS60 is ischemic stroke with additional programs in ALS and other neurological disorders. The company's pioneering technology, founded in physics, addresses fundamental mechanisms involved with proper cellular function to slow disease progression and improve quality of life. For more information, please visit revalesio.com and engage with us on LinkedIn. Media Lori Murray [email protected] SOURCE Revalesio Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Orphan DrugFast Track

17 Sep 2024

·www.biospace.com

Revalesio’s Investigational RNS60 Extended Survival in Patients with Amyotrophic Lateral Sclerosis (ALS) in Post-Hoc Analysis of Phase 2 Investigator-Sponsored Trial

RNS60 Also Slowed the Decline of Respiratory Function in ALS Patients Results Published in Brain, Behavior, and Immunity TACOMA, Wash. , Sept. 17, 2024 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced the publication of data in the journal Brain, Behavior, and Immunity , showing that Revalesio’s investigational therapeutic, RNS60, extended median survival by 6 months compared to placebo in a post-hoc analysis of a Phase 2 investigator-sponsored trial. The trial was coordinated by the Research Center for ALS, Istituto di Ricerche Farmacologiche Mario Negri IRCCS in Milano, Italy . After a 6-month double-blind treatment phase, participants were followed for a mean duration of 2.8 years and monitored for survival. Median survival was 6 months longer in the RNS60 treatment group compared to placebo (3 years vs. 2.4 years, p = 0.0519). As reported by the trial investigators in an earlier publication, the decline of forced vital capacity (FVC) - the maximum volume of air that a patient can exhale after a maximum inspiration, used as a primary test to evaluate breathing function of people living with ALS - was significantly slower in the RNS60 group compared to the placebo group at the end of treatment (FVC, difference 0.41 per week, standard error 0.16, p = 0.0101), showing a positive effect of RNS60 on respiratory and bulbar function. The new analysis showed that the extension of survival correlated with the rate of decline of FVC (median survival was 3.7 years in participants with a slow decline of FVC and 1.6 years in participants with faster FVC decline, p < 0.0001). Survival in the RNS60 group was significantly longer compared to the placebo group in participants with low baseline levels of neurofilament light chain, NfL (p = 0.012) or monocyte chemoattractant protein-1, MCP-1 (p < 0.01). Blood levels of NfL, a marker of neuronal damage, have been shown to correlate with the progression rate of ALS. MCP-1 is an inflammatory marker whose blood levels have been reported to increase during the course of ALS. These biomarker results suggest that this could be a subgroup to target in future studies investigating the effects of RNS60 on survival. “These promising findings suggest that RNS60 may have a beneficial effect on survival and slowing the decline of respiratory function in patients with ALS,” said Letizia Mazzini , Professor of Neurology and Director of the Tertiary ALS Center at the University of Piemonte Orientale and participating center in the Phase 2 clinical trial. “These results warrant further investigation, and I look forward to the future development of RNS60 for the treatment of ALS.” “With these encouraging results, RNS60 has shown benefit across two randomized clinical trials in ALS and ischemic stroke, underscoring its potential to impact patients with both acute and chronic neurological disorders. We are committed to advancing RNS60 in additional clinical trials to further evaluate RNS60’s potential to benefit people with ALS and other neurological disorders,” said Bert van den Bergh , Revalesio’s Executive Chairman on the Board of Directors, and former President of Neuroscience Products at Eli Lilly and Company. “On behalf of Revalesio, I would like to thank the investigators for conducting this important additional analysis, as well as the patients and their families for their participation. I would also like to thank the ALS Association for contributing to the original study through the ALS Ice Bucket Challenge.” RNS60 Phase 2 Clinical Trial Design The investigator-sponsored study was a multi-center, randomized, double-blind, placebo-controlled Phase 2 clinical trial, evaluating 147 people living ALS. Patients were enrolled across 22 Italian expert ALS centers and randomized to either RNS60 (n=74) or placebo (n=73) for 24 weeks. Participants were diagnosed with ALS and classified as slow or fast progressors with respect to FVC based on the FVC slope of decline during trial treatment. The primary endpoints were safety and certain biomarker levels associated with ALS and secondary endpoints were the ALS functional rating scale, FVC and survival. Following the 6-month treatment phase, participants were monitored for survival to support the post-hoc analysis. About RNS60 RNS60 is an investigational therapeutic being developed to provide disease modifying and potentially restorative treatments for neurological diseases. In preclinical studies, RNS60 activated intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protected neurons and oligodendrocytes and modulated the activity of immune cells to restore homeostasis. RNS60 has been granted Orphan Drug and Fast Track designations for ALS from the U.S. Food and Drug Administration. About Revalesio Revalesio is a clinical-stage pharmaceutical company with a vision to change the future of treatment for acute and chronic neurological disorders. The company’s lead clinical program for RNS60 is ischemic stroke with additional programs in ALS and other neurological disorders. The company’s pioneering technology, founded in physics, addresses fundamental mechanisms involved with proper cellular function to slow disease progression and improve quality of life. For more information, please visit revalesio.com and engage with us on LinkedIn . Media Lori Murray lori.murray@captivate-comms.com View original content to download multimedia: SOURCE Revalesio

Phase 2Clinical ResultOrphan DrugFast Track

100 Deals associated with RNS-60

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Amyotrophic Lateral Sclerosis	Phase 2	-	Revalesio Corp.	01 Oct 2025
Ischemic stroke	Phase 2	United States	Revalesio Corp.	07 Jul 2021
Lacerations	Preclinical	United States	Revalesio Corp.	09 Dec 2013
Anterior Cruciate Ligament Injuries	Preclinical	-	Revalesio Corp.	14 Aug 2013
Pain, Postoperative	Preclinical	-	Revalesio Corp.	14 Aug 2013
Multiple Sclerosis, Relapsing-Remitting	Preclinical	United States	Revalesio Corp.	25 Oct 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04693715 (RESCUE, PRNewswire) Manual	Phase 2	Acute Ischemic Stroke	-	RNS60 1.0 mL/kg/h (high dose)	(rhvqdxxxsx) = curwycqwpy aprcwfanxg (vbxlblssdt ) View more	Positive	05 Feb 2025
				RNS60 0.5 mL/kg/h (low dose)	-
EUCTR2016-002382-62-IT \| NCT03456882 (Pubmed \| Brain Behav Immun)	Phase 2	Amyotrophic Lateral Sclerosis forced vital capacity (FVC) slope \| neurofilament light chain (NfL) \| Monocyte Chemoattractant Protein-1 (MCP-1)	-	RNS60	fgktyxmgsu(plbdgvjhua) = After 6 months of randomized, placebo-controlled treatment, FVC decline was significantly slower in the RNS60 group compared to the placebo group ivqxyqdfcr (ijbkqzvwse ) View more	Positive	01 Nov 2024
				Placebo
NCT03456882 (RNS60 \| ###DELETE \| EUDRA-CT (2016-002382-62), CTgov)	Phase 2	Amyotrophic Lateral Sclerosis	147	RNS60 (RNS60)	hjdzhjvqbc(dtugddtigc) = puzfkwbohr hihppoloxx (csxvbograw, iaqxlilzdr - tzkuvkkeph) View more	-	21 Apr 2023
				RNS60 (NORMAL SALINE)	hjdzhjvqbc(dtugddtigc) = aypvojyioq hihppoloxx (csxvbograw, ncomdevtit - zqtncnbypg) View more
NCT02525471 (CTgov)	Phase 1	Amyotrophic Lateral Sclerosis	24	RNS60	taeblizwyo(ebwfgdtyto) = mqpduyxkaw aqkligdfwq (jmlnqorznb, xvqvzdbmpi - xusbnossvh) View more	-	03 Mar 2021
Nano Cl iv (ECTRIMS2019)	Phase 2	Clinically isolated syndrome \| Multiple Sclerosis, Relapsing-Remitting	36	RNS60	logwyffnns(bphwdgwtcg) = evxfcblrnh aozvwzjdmc (rfmvvqylqc, 0.42 - 1.06)	Positive	10 Sep 2019
MP62-13 (AUA2019)	Not Applicable	Pudendal Neuralgia BDNF \| TrkB	-	PNC + Saline	adhmeewrdq(gmupcdzisl) = jfldudcaeh yuowakwfqi (rnyubhefdh ) View more	-	01 Apr 2019
				PNC + TrkB	adhmeewrdq(gmupcdzisl) = clfgghkdqp yuowakwfqi (rnyubhefdh ) View more
ISC2015	Not Applicable	Stroke	10	MST-188 + tPA	jshveuqwxp(jqgxlrhqvf) = odoghztjmn owwelsurms (vxsyepuine )	Positive	01 Feb 2015
				tPA	jshveuqwxp(jqgxlrhqvf) = yawbxssnnm owwelsurms (vxsyepuine )
1007 (AUA2010)	Not Applicable	Urinary Bladder, Overactive	14	Ganirelix	tvrpurriqm(qnwrxebmvi) = ppkmcxcdax cfpydbenjs (zgbosfcaqm ) View more	-	01 Apr 2010
				Saline vehicle	tvrpurriqm(qnwrxebmvi) = lbatqynavf cfpydbenjs (zgbosfcaqm ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

RNS-60

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation